अApnaFunda
Menu

BAJAJ HEALTHCARE LIMITED (BAJAJHCARE)

Health Technology · Pharmaceuticals: Major · figures to Nov '26

Quality scoreHow the business itself ranks against its sector peers on profitability, 3-year growth and leverage. 50 is the middle of the sector.29 / 100
Profitability 44Growth 11Balance sheet 31
Momentum scoreHow strong the recent trend is: 3-month price change, 12-month improvement in earnings and the rise in FII + DII holding, among companies above ₹500 cr.46 / 100
Price 54Earnings 40FII/DII 45
Compare withSUN PHARMACEUTICAL INDUSTRIESDIVIS LABORATORIESTORRENT PHARMACEUTICALS

Share price

Closing priceAdjusted for splits and bonus issues.

₹315.25 latest close · −8.5% over the last 90 sessions

₹300₹325₹350₹375Jul 3Jul 29Aug 24Sep 17Oct 14Nov 9 ₹300₹325₹350₹375Jul 3Sep 4Nov 9

₹315.25 month-end · −27.1% over 12 months

₹300₹350₹400Nov '25Jan '26Apr '26Jun '26Sep '26Nov '26 ₹300₹350₹400Nov '25May '26Nov '26

₹315.25 month-end · −18.8% over 3 years

₹400₹600Nov '23Jun '24Jan '25Sep '25Apr '26Nov '26 ₹400₹600Nov '23May '25Nov '26

₹315.25 month-end · −10.1% since Nov '21

₹400₹600Nov '21Nov '22Nov '23Nov '24Nov '25Nov '26 ₹400₹600Nov '21May '24Nov '26

52-week range ₹272.35 to ₹481.80 · 1-year volatility 42.3%

Was the rally earned?

-27%share price, 1 yearEarnings-driven

Mostly earnings.

  • Per-share earnings took off 76 points, while the multiple moved less (P/E 30.9x to 54.7x).
  • The share count rose 4%.
Net profit growth: −73 pts. Points of the price return explained by net profit growing (or shrinking).−73 ptsNet profit growthP/E change: +49 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+49 ptsP/E changeShare count change: −3 pts. Points of the price return explained by the share count changing. More shares count against the price.−3 ptsShare count changeShare price: −27%−27%Share priceNet profit growth: −73 pts. Points of the price return explained by net profit growing (or shrinking).−73ProfitP/E change: +49 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+49P/EShare count change: −3 pts. Points of the price return explained by the share count changing. More shares count against the price.−3SharesShare price: −27%−27%Share price
Net profit growth-73 ptsNet profit fell about 57%, which lowers the price.
P/E change+49 ptsThe P/E rose from 30.9x to 54.7x, which lifts the price.
Share count change-3 ptsShare count rose 4%, which lowers the price.
-19%share price, 3 yearsEarnings-driven

Mostly earnings.

  • Per-share earnings took off 90 points, while the multiple moved less (P/E 24.9x to 54.7x).
  • The share count rose 18%.
Net profit growth: −75 pts. Points of the price return explained by net profit growing (or shrinking).−75 ptsNet profit growthP/E change: +71 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+71 ptsP/E changeShare count change: −15 pts. Points of the price return explained by the share count changing. More shares count against the price.−15 ptsShare count changeShare price: −19%−19%Share priceNet profit growth: −75 pts. Points of the price return explained by net profit growing (or shrinking).−75ProfitP/E change: +71 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+71P/EShare count change: −15 pts. Points of the price return explained by the share count changing. More shares count against the price.−15SharesShare price: −19%−19%Share price
Net profit growth-75 ptsNet profit fell about 56%, which lowers the price.
P/E change+71 ptsThe P/E rose from 24.9x to 54.7x, which lifts the price.
Share count change-15 ptsShare count rose 18%, which lowers the price.
-10%share price, 5 yearsEarnings-driven

Mostly earnings.

  • Per-share earnings took off 157 points, while the multiple moved less (P/E 11.6x to 54.7x).
  • The share count rose 19%.
Net profit growth: −141 pts. Points of the price return explained by net profit growing (or shrinking).−141 ptsNet profit growthP/E change: +147 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+147 ptsP/E changeShare count change: −16 pts. Points of the price return explained by the share count changing. More shares count against the price.−16 ptsShare count changeShare price: −10%−10%Share priceNet profit growth: −141 pts. Points of the price return explained by net profit growing (or shrinking).−141ProfitP/E change: +147 pts. Points of the price return explained by the market paying a higher or lower P/E multiple.+147P/EShare count change: −16 pts. Points of the price return explained by the share count changing. More shares count against the price.−16SharesShare price: −10%−10%Share price
Net profit growth-141 ptsNet profit fell about 77%, which lowers the price.
P/E change+147 ptsThe P/E rose from 11.6x to 54.7x, which lifts the price.
Share count change-16 ptsShare count rose 19%, which lowers the price.
What do "pts" mean?

"pts" are percentage points of the share price return. The parts add up to the total shown for each period. Because price = P/E × net profit ÷ share count, higher profit pushes the price up, a higher P/E pushes it up, and more shares push it down.

Example: if the price rose 34% and profit growth accounts for +58 pts while a lower P/E accounts for -24 pts, then 58 - 24 = 34. The +58 is not the profit growth rate itself: it is the part of the price move that profit growth explains.

Net profit is trailing twelve months as reported with a 60-day lag.

Compare this with SUN PHARMACEUTICAL INDUSTRIES

How rough has the ride been?

Maximum drawdown-61.4%not yet recovered
1-year volatility42.3%annualised
Beta vs sector index1.123-year daily, correlation 0.34
Volume spikes3last 90 sessions, 5x the 50-day median

Drawdown from peak

0%−20%−40%−60%2023202420252026−60.1% 0%−20%−40%−60%20242026−60.1%
Largest drawdowns

-61.4% (2025-03 peak to 2026-05 low, not yet recovered)

-45.7% (2022-01 peak to 2022-06 low, recovered 2023-10)

-43.9% (2023-10 peak to 2024-06 low, recovered 2024-12)

Most recent volume spikes

2026-07-22: 10.1x the 50-day median, price -12.5% that day

2026-07-21: 5.6x the 50-day median, price -4.4% that day

2026-07-20: 6.2x the 50-day median, price +3.4% that day

Beta is the slope of daily returns against a market-cap-weighted index of the sector's other listed companies, built from today's constituents (so it excludes companies no longer listed).

Is it expensive against its own past and its peers?

54.7xP/E todayNear its historic high
Against its own history92nd percentile
CheapestMedian 20.6xDearest

Usual range 11.6x to 53.5x since 2021-11.

Against Health Technology54.7x vs 37.0x
This company
54.7x
Sector median
37.0x

48% above the Health Technology median.

10.3x28.4x46.5x64.6xNov '21Nov '22Nov '23Nov '24Nov '25Nov '2610.3x28.4x46.5x64.6xNov '21Jul '23Mar '25Nov '26
P/E (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/B (this company)10th to 90th percentile of its own historyIts medianHealth Technology median

The chart loads when you open this tab.

P/S (this company)10th to 90th percentile of its own historyIts medianHealth Technology median
How to read this

Shaded band: 10th to 90th percentile of the company's own P/E history; dotted line: its median; orange line: sector median (companies with a positive multiple, at least 5 in the sector).

Sector figures are built from today's listed companies, so they exclude companies that are no longer listed.

All terms explained in the glossary →

How Health Technology is valued

Where does it rank among Health Technology peers?

Each cell is the company's percentile rank among its Health Technology peers (non-financial companies) that month.
Darker is better-ranked.
Rows marked ↓ are inverted (lower debt, shorter cash cycle and a lower P/E rank higher).

Where it ranks today

  • ROCE36thflat vs a year ago
  • Op. margin52nd▲ 5 pts vs a year ago
  • Revenue growth52nd▼ 25 pts vs a year ago
  • EPS growth15th
  • Debt/equity ↓24thflat vs a year ago
  • Cash cycle ↓23rd▲ 5 pts vs a year ago
  • P/E ↓26th▼ 26 pts vs a year ago
  • 12M momentum10th▼ 72 pts vs a year ago

Rank history

ROCE
Op. margin
Revenue growth
EPS growth
Debt/equity ↓
Cash cycle ↓
P/E ↓
12M momentum
Dec '21Jul '22Jan '23Jul '23Jan '24Jul '24Jan '25Jul '25Jan '26Jul '26Nov '26
Lower rank Higher rank Not enough data

Percentiles use today's listed companies in the sector and need at least 5 peers with a value; grey cells have too few.
ROE is computed from net profit and book value where the source does not report it.

The Health Technology sector page Watch it move against Health Technology in the Observatory

What is the price implying?

~28%annual earnings growth implied by the price

At a P/E of 57.3x, the price would imply about 27.8%/yr earnings growth for 10 years under the same assumptions, but it is not ranked.

Fewer than six years of annual earnings are available, which is too little to measure delivered growth.

“Implied growth” is what the current price would require under our stated assumptions, not what we expect.

What prices imply across Health Technology The market-wide Expectations lists

Key figures

Share Priceclose 9 Nov
₹315.25
P/E
54.7x
ROCE
11.0%
Market Cap
₹1062 cr
Revenue (TTM)
₹628 cr
P/S
1.7x
P/B
2.0x
ROE
3.6%
Operating Margin
17.0%
Debt / Equity
0.5x
Promoter Holding
58.6%
12M Momentum
-27.1%

52-week range

₹272.35₹481.80
20% of the way from its 52-week low to its high

Price risk

1Y volatility
42.3%
Beta vs sector
1-year daily
1.31

Balance sheet & cash

Interest cover
operating profit ÷ interest
2.0x
Cash from profit, 3Y
operating cash flow ÷ net profit
2.37x
Share count, 1Y
+6.3%

Are profits backed by cash?

5 of 6checks within range1 near a threshold
Other income reliance-100%Within range

Other income as a share of pre-tax profit (trailing twelve months): -100.0%. Bands: below 15%, 15% to 35%, above 35%.

Tax rate17%Within range

Median quarterly effective tax rate over about 2.5 years: 17.0%. Bands: 15% to 35%, 5% to 15% or 35% to 50%, outside 5% to 50%.

Cash conversion—Not enough data

Not enough reported data to compute this.

Free cash flow3 of 5 yrsNear threshold

Fiscal years with positive free cash flow in the last 5: 3. Bands: at least 80% of years, 40% to 80%, below 40%.

Receivable days vs history+1 daysWithin range

Debtor days are above the median of the previous three fiscal years by 1 days (140 vs 139). Bands: under 15 days, 15 to 45, over 45.

Capital work in progress3% of fixed assetsWithin range

Capital work-in-progress is 3% of fixed assets. Bands: not rising or up to 30%; rising for three years and above 30%; rising and above 60%.

Payable days+5 days / 2 yrsWithin range

Days payable changed by +5 over two years. Bands: rise of up to 30 days; more than 30 days.

Tap a check to see how it is measured

How to read this

Each check is a named rule with fixed thresholds, not a score. Annual statements are the latest restated figures, so a past year may differ from what was originally reported.

All terms explained in the glossary →

Who has been buying and selling?

  • Over 3 years, promoters trimmed 9.1 pts; FIIs added 1.5 pts; DIIs added 1.5 pts.
  • The number of shareholders rose from 28,008 to 41,310 (+47%) between Sep 2023 and Jun 2026.

Holdings, Jun '26

How each group changed

GroupSep '23Jun '26Change
Promoters67.7%58.6%-9.1 pts
FIIs0.7%2.2%+1.5 pts
DIIs0.4%1.9%+1.5 pts
Public and others31.2%37.3%+6.1 pts

Number of shareholders

41,310shareholders+47% since Sep '23
28k32k37k41k Sep '23Jun '24Mar '25Dec '25Jun '26
Sep '23: 28,008
Dec '23: 29,626
Mar '24: 32,712
Jun '24: 32,397
Sep '24: 31,995
Dec '24: 32,672
Mar '25: 35,710
Jun '25: 35,980
Sep '25: 38,576
Dec '25: 37,953
Mar '26: 38,158
Jun '26: 41,310
 28k32k37k41k Sep '23Sep '24Sep '25Jun '26
Sep '23: 28,008
Dec '23: 29,626
Mar '24: 32,712
Jun '24: 32,397
Sep '24: 31,995
Dec '24: 32,672
Mar '25: 35,710
Jun '25: 35,980
Sep '25: 38,576
Dec '25: 37,953
Mar '26: 38,158
Jun '26: 41,310

Quarterly shareholding as reported, labelled by the quarter it covers (it becomes visible about two months later).
Shareholder counts are only available for recent quarters.

This quarter's smart-money board

What happened next to similar setups

+2.3%typical 12-month return vs the marketNot meaningfully different from the base rate
  • We found 50 past situations where a non-financial company looked like BAJAJ HEALTHCARE LIMITED today on valuation, return on capital, margins, debt, growth, price momentum, size and volatility.
  • Over the following 12 months the middle half of them returned −22% to +62% vs the market, against 0% for all non-financial companies in the same months.
  • The gap against the base rate (+2.6%, 80% range −9.4% to +6.1%) is within what chance and overlapping periods produce.

Where the 50 outcomes landed

−100%−50%0%+50%+100%
STANLEY · Aug 2025: −58.1% vs market
SDBL · Jan 2020: −53.4% vs market
CAMLINFINE · Oct 2023: −47.8% vs market
DYNPRO · Jul 2022: −43.4% vs market
REPRO · Jun 2020: −42.9% vs market
SNOWMAN · Jan 2025: −41.0% vs market
HILTON · Feb 2024: −40.4% vs market
SHILPAMED · Jun 2022: −39.2% vs market
MEDPLUS · Apr 2023: −36.2% vs market
AERONEU · Jan 2024: −29.1% vs market
KOKUYOCMLN · Mar 2020: −24.4% vs market
JINDWORLD · Aug 2020: −22.6% vs market
VIPCLOTHNG · Nov 2023: −22.2% vs market
GOCLCORP · Apr 2020: −21.4% vs market
SHALBY · Apr 2025: −20.6% vs market
DOLLAR · Jul 2023: −20.5% vs market
ASALCBR · May 2022: −17.8% vs market
LUMAXIND · Jun 2021: −16.3% vs market
AMBER · Jul 2022: −14.9% vs market
DPSCLTD · Aug 2023: −8.1% vs market
EVEREADY · Apr 2024: −7.6% vs market
EXXARO · Oct 2022: −7.5% vs market
ASIANTILES · May 2020: −6.7% vs market
ALICON · Aug 2022: −1.1% vs market
SOUTHWEST · Aug 2024: +1.8% vs market
SHK · Feb 2021: +2.8% vs market
SOMANYCERA · Jul 2022: +3.3% vs market
DMCC · Mar 2024: +4.6% vs market
VMART · Sep 2025: +5.6% vs market
RAJRATAN · Jun 2025: +7.2% vs market
HLEGLAS · Apr 2025: +10.4% vs market
ROHLTD · Feb 2021: +15.7% vs market
NELCAST · Dec 2021: +18.5% vs market
YUKEN · Jan 2024: +23.5% vs market
GUFICBIO · Oct 2025: +34.3% vs market
STYRENIX · Nov 2020: +42.2% vs market
KCP · Aug 2020: +45.8% vs market
BEML · Feb 2023: +67.9% vs market
AVALON · May 2024: +68.1% vs market
ORIENTCEM · May 2020: +69.7% vs market
MINDACORP · Aug 2021: +76.1% vs market
SAGCEM · Aug 2020: +85.7% vs market
JPPOWER · Jan 2023: +86.5% vs market
ACLGATI · May 2020: +88.9% vs market
SOBHA · Aug 2023: +93.1% vs market
HINDWAREAP · Dec 2020: +95.5% vs market
AXISCADES · Aug 2024: +109.6% vs market
SHAILY · Aug 2023: +109.9% vs market
SCHNEIDER · Jun 2022: +119.0% vs market
RAMCOSYS · Jul 2020: +141.4% vs market
Similar setups +2.3%All companies −0.3%← worse than the marketbetter than the market →

Each dot is one past situation (hover or tap for details) · Solid dots are the closest matches, listed below · Shaded is the middle half of all companies in the same months · 4 beyond the range shown, drawn at the edge

Similar setups' median
+2.3%
All companies' median
−0.3%
Beat the market
52% vs 50%

50 past situations · 50 companies · 37 months · 2020–2025

The closest matches

CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
SAGCEM
Non-Energy Minerals		 Aug 2020 39x8% −17%−26% +86%
YUKEN
Producer Manufacturing		 Jan 2024 88x8% +22%−13% +24%
KOKUYOCMLN
Consumer Durables		 Mar 2020 27x9% −58%−60% −24%
DMCC
Process Industries		 Mar 2024 98x7% +14%−25% +5%
ALICON
Producer Manufacturing		 Aug 2022 53x9% −1%−19% −1%
Show the other 3 matches
CompanyWhenP/EROCE12M mom.DrawdownNext 12 months
SCHNEIDER
Distribution Services		 Jun 2022 85x14% −23%−34% +119%
ACLGATI
Transportation		 May 2020 22x7% −52%−56% +89%
CAMLINFINE
Process Industries		 Oct 2023 48x10% −8%−21% −48%
How reliable is this?

Matched on P/E, P/S, ROCE, operating margin, debt/equity, interest cover, revenue growth, 12-month momentum, drawdown from 12-month high, size and volatility. Closest on: 12-month momentum, drawdown from 12-month high and P/S. One match per company and at most 7 from any one month.

Independent periods: the matches fall in 6 distinct 12-month windows. Matches from nearby months share the same market conditions, so fewer windows means less evidence.

How this is built

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to BAJAJ HEALTHCARE LIMITED. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

Methodology

How historical analogs are built

Data as of 2026-11-09. Outcome pool: Jan 2020 to Oct 2025.

For every company we look at the situation it is in today (valuation, return on capital, margins, debt, growth, 12-month price momentum, drawdown, size and volatility) and find past company-months that looked most like it. We then show what happened to those past situations over the following 12 months, measured against the ApnaFunda All index and against the base rate. It describes history. It does not predict anything.

What is compared

FeatureWeightNon-financialFinancial
P/E1yesyes
P/S1yes—
P/B1—yes
ROCE1yes—
operating margin1yes—
ROE1—yes
debt/equity0.75yes—
interest cover0.5yes—
revenue growth0.75yesyes
12-month momentum1yesyes
drawdown from 12-month high0.75yesyes
size0.75yesyes
volatility0.5yesyes

Weights were set by judgement before any outcome was looked at and are never tuned on results. Loss-making companies (negative P/E or net profit) are only matched with other loss-making companies. Banks, NBFCs and insurers are compared only with each other and use a different feature set. Every feature is converted, month by month, to its rank among companies in the same pool in that month, so a P/E of 30 in a hot market and a P/E of 22 in a cold one can match if both were equally expensive for their time. Only that month's data is used.

How closeness and the sample are defined

Distance is the weighted root-mean-square gap between the standardised features both companies have. A match needs at least 70% of the query's feature weight, a distance of at most 0.9, and 30 matches at minimum to be shown. We keep up to 50 matches with these exclusions: never the company itself, one match per company (its closest month), and at most 7 from any one calendar month so a single market episode cannot dominate.

Base rate

The base rate is the distribution of 12-month returns, relative to the market, of every eligible company-month in the same pool, with each month weighted to match the months the analogs came from. It answers: how did a random company do in these same months? Because matches from nearby months share the same market conditions, we also report the number of distinct 12-month windows behind a result, and a bootstrap that resamples months decides whether the analog median differs from the base rate at all. "Not meaningfully different" is the usual outcome and the page copy is written for it.

Limits you should know

  • One market period. The outcome pool covers 2020–2025 only (70 months), including the 2020 crash and the 2020–21 rally.
  • Survivorship. Only companies listed today are included. Delisted and bankrupt companies are missing, which flatters past outcomes, particularly for distressed-looking setups.
  • Price return only. Dividends are excluded, and the benchmark is an ApnaFunda market-cap-weighted index of the same listed companies, not an official index.
  • Reporting lag. Fundamentals are matched on an assumed 60-day lag after the quarter end, not on real announcement dates.
  • Pools: non-financial: 98,395 company-months from 2019 companies; financial: 5,659 company-months from 108 companies. 2349 companies currently have a result; the rest are suppressed because too few comparable situations exist.

Does it work? A walk-forward check

The walk-forward check has not been run for this build, so skill is shown as not yet measured.

Disclaimer

This is history, not a forecast. These are past situations where other companies had broadly similar reported numbers and price trends. What happened to them does not tell you what will happen to any company shown. The comparison covers only 2020–2025, a single market period, and only companies still listed today. Companies that were delisted or went bankrupt are missing, which makes past outcomes look better than they were. Returns exclude dividends and are measured against an ApnaFunda-built index, not an official benchmark. Fundamentals are matched on a 60-day assumed reporting lag, not actual announcement dates. Its historical skill has not yet been measured. Past patterns may not repeat.

What else looks like this?

Companies with the most similar financial profile today, regardless of industry.

SARLA PERFORMANCE FIBERSSARLAPOLY
Process Industries
74%similar
EPS growthpromoter holding
STANLEY LIFESTYLESSTANLEY
Consumer Durables
68%similar
operating marginpromoter holding
FAIRCHEM ORGANICSFAIRCHEMOR
Process Industries
67%similar
EPS growthvolatility
NELCONELCO
Electronic Technology
63%similar
revenue growthEPS growth
LOKESH MACHINESLOKESHMACH
Technology Services
59%similar
EPS growthoperating margin
AMANTA HEALTHCAREAMANTA
Health Technology
65%similar
P/EROCE
KOPRANKOPRAN
Health Technology
50%similar
revenueP/E
INDOCO REMEDIESINDOCO
Health Technology
47%similar
promoter holdingEPS growth

Similarity is statistical, based on reported metrics; it does not imply similar business quality or future returns.

What changed?

30 events since Jun '24

  1. SepPeer rankMoved into the 2nd quartile of Health Technology on operating margin (from the 3rd quartile).
  2. JulSharesShare count is up 6.2% over 12 months.
  3. JulPriceVolume reached 10.1x its 50-day median on 2026-07-22; price -12.5% that day.
  4. JunValuationP/E crossed above the 90th percentile of its own history to date (64.6x).
  5. JunPeer rankSlipped to the 3rd quartile of Health Technology on operating margin (from the 2nd quartile).
  6. JunPriceVolume reached 105.7x its 50-day median on 2026-06-29; price +16.0% that day.
  7. MayPriceFell 61% from the Mar 2025 peak to the May 2026 low.
  8. MarPriceVolume reached 9.2x its 50-day median on 2026-03-18; price +10.7% that day.
Show 22 earlier events
  1. FebDebtDebt / equity halved over 12 months to 0.48x.
  2. DecPeer rankMoved into the 2nd quartile of Health Technology on operating margin (from the 3rd quartile).
  3. NovPriceVolume reached 8.7x its 50-day median on 2025-11-28; price +1.4% that day.
  4. SepPeer rankMoved into the 3rd quartile of Health Technology on operating margin (from the bottom quartile).
  5. SepPriceVolume reached 38.9x its 50-day median on 2025-09-24; price +9.5% that day.
  6. JulDebtDebt / equity halved over 12 months to 0.48x.
  7. JunResultsEPS (TTM) turned positive.
  8. JunValuationP/E crossed above the 90th percentile of its own history to date (39.3x).
  9. JunPeer rankSlipped to the bottom quartile of Health Technology on operating margin (from the 2nd quartile).
  10. JunDebtDebt / equity fell below 1.0x (0.48x).
  11. JunDividendStarted paying a dividend (payout 8% of profit).
  12. JunSharesShare count is up 14.3% over 12 months.
  13. JanPriceVolume reached 27.7x its 50-day median on 2025-01-01; price +10.3% that day.
  14. DecPromoterPromoter holding fell 8.5 pts to 59.2%.
  15. DecPriceRegained the 2023-10 peak, 6 months after the low.
  16. DecInstitutionsFII + DII holding rose 3.0 pts over 1 quarter to 3.0%.
  17. DecPriceVolume reached 64.1x its 50-day median on 2024-12-19; price +4.8% that day.
  18. JulPriceVolume reached 92.0x its 50-day median on 2024-07-05; price +8.1% that day.
  19. JunResultsEPS (TTM) turned negative.
  20. JunPriceFell 44% from the Oct 2023 peak to the Jun 2024 low.
  21. JunPeer rankSlipped to the 3rd quartile of Health Technology on ROCE (from the 2nd quartile).
  22. JunDividendDividend payout cut from 6% to -3% of profit.

Events are generated from the data by fixed rules.
The month shown is when the change became visible in the reported figures, assuming a 60-day lag after each quarter end; it is not an announcement date.

Where price and fundamentals disagree, market-wide Rewind the whole market to any month

Monthly history61 months · 2021-11 to 2026-11
MonthP/ERevenue (TTM)ROEROCEDebt / Equity
2026-1154.7x₹628 cr3.6%11.0%0.5x
2026-1053.2x₹628 cr3.5%11.0%0.5x
2026-0956.8x₹628 cr3.5%11.0%0.5x
2026-0861.3x₹611 cr3.1%11.0%0.5x
2026-0761.8x₹611 cr3.1%11.0%0.5x
2026-0664.6x₹611 cr3.1%11.0%0.5x
2026-0519.2x₹612 cr11.1%11.0%0.5x
2026-0420.4x₹612 cr11.1%11.0%0.5x
2026-0318.4x₹612 cr11.1%11.0%0.5x
2026-0222.7x₹574 cr10.2%11.0%0.5x
2026-0123.8x₹574 cr10.2%11.0%0.5x
2025-1228.6x₹574 cr10.2%11.0%0.5x
2025-1130.9x₹559 cr9.7%11.0%0.5x
2025-1034.0x₹559 cr9.7%11.0%0.5x
2025-0934.7x₹559 cr9.7%11.0%0.5x
2025-0832.9x₹542 cr8.6%11.0%0.5x
2025-0737.9x₹542 cr8.6%11.0%0.5x
2025-0639.3x₹542 cr8.6%11.0%0.5x
2025-05—₹522 cr-1.5%8.0%1.2x
2025-04—₹522 cr-1.5%8.0%1.2x
2025-03—₹522 cr-1.5%8.0%1.2x
2025-02—₹508 cr-5.9%8.0%1.2x
2025-01—₹508 cr-5.9%8.0%1.2x
2024-12—₹508 cr-5.9%8.0%1.2x
2024-11—₹476 cr-10.4%8.0%1.2x
2024-10—₹476 cr-10.4%8.0%1.2x
2024-09—₹476 cr-10.4%8.0%1.2x
2024-08—₹473 cr-31.1%8.0%1.2x
2024-07—₹473 cr-31.1%8.0%1.2x
2024-06—₹473 cr-31.1%8.0%1.2x
2024-0518.5x₹646 cr12.1%14.0%1.1x
2024-0420.9x₹646 cr12.1%14.0%1.1x
2024-0318.7x₹646 cr12.1%14.0%1.1x
2024-0221.5x₹646 cr12.1%14.0%1.1x
2024-0121.4x₹646 cr12.1%14.0%1.1x
2023-1224.1x₹646 cr12.1%14.0%1.1x
2023-1124.9x₹646 cr12.1%14.0%1.1x
2023-1026.5x₹646 cr12.1%14.0%1.1x
2023-0930.3x₹646 cr12.1%14.0%1.1x
2023-0823.7x₹646 cr12.1%14.0%1.1x
2023-0723.7x₹646 cr12.1%14.0%1.1x
2023-0620.6x₹646 cr12.1%14.0%1.1x
2023-0511.6x₹680 cr22.3%20.0%0.8x
2023-0412.0x₹680 cr22.3%20.0%0.8x
2023-0311.9x₹680 cr22.3%20.0%0.8x
2023-0213.4x₹680 cr22.3%20.0%0.8x
2023-0115.6x₹680 cr22.3%20.0%0.8x
2022-1217.2x₹680 cr22.3%20.0%0.8x
2022-1115.4x₹680 cr22.3%20.0%0.8x
2022-1014.1x₹680 cr22.3%20.0%0.8x
2022-0913.6x₹680 cr22.3%20.0%0.8x
2022-0813.9x₹680 cr22.3%20.0%0.8x
2022-0715.1x₹680 cr22.3%20.0%0.8x
2022-0610.6x₹680 cr22.3%20.0%0.8x
2022-0510.3x₹657 cr33.1%36.0%0.7x
2022-0411.3x₹657 cr33.1%36.0%0.7x
2022-0311.3x₹657 cr33.1%36.0%0.7x
2022-0212.9x₹657 cr33.1%36.0%0.7x
2022-0113.4x₹657 cr33.1%36.0%0.7x
2021-1213.7x₹657 cr33.1%36.0%0.7x
2021-1111.6x₹657 cr33.1%36.0%0.7x

Methodology and data notes

Methodology

Methodology and data notes

All figures come from public exchange prices and screener.in financial statements. Quarterly and annual results are shown from 60 days after the period end, so a month never uses a result before it would plausibly have been published. Statements are the latest versions, which may include later restatements.

Sector medians, percentiles and indices use today's listed companies in the sector (survivorship bias). Prices are adjusted for splits and bonus issues; around a corporate action the fundamentals may lag the price by up to a month, and affected sections are hidden.

The return decomposition uses price = P/E × net profit ÷ share count. The reverse DCF uses a fixed 12% cost of equity, a 10-year horizon and a 15x terminal P/E, and is an illustration only. Events, flags and twins follow fixed rules and thresholds described next to each section.

Feedback